Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias.
frontotemporal dementia
progranulin
validation
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
27 11 2023
27 11 2023
Historique:
received:
29
05
2023
accepted:
29
06
2023
medline:
26
10
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
Heterozygous mutations in the granulin ( Analytical validation parameters including assay precision, selectivity, measurement range, dilution linearity, interferences and sample stability were tested according to previously described procedures. For clinical validation, PGRN levels were measured in plasma from 32 cognitively healthy individuals, 52 confirmed Among the analytical validation parameters, assay precision and repeatability were very stable (coefficients of variation <7 %). Spike recovery was 96 %, the measurement range was 6.25-400 μg/L and dilution linearity ranged from 1:50-1:200. Hemolysis did not interfere with progranulin levels, and these were resistant to freeze/thaw cycles and storage at different temperatures. For the clinical validation, the assay was capable of distinguishing In this study, we demonstrate robust analytical and diagnostic performance of this commercial progranulin kit for implementation in clinical laboratory practice. This easy-to-use test allows identification of potential
Identifiants
pubmed: 37476993
pii: cclm-2023-0562
doi: 10.1515/cclm-2023-0562
pmc: PMC10598571
doi:
Substances chimiques
Progranulins
0
Intercellular Signaling Peptides and Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2195-2204Subventions
Organisme : NIA NIH HHS
ID : R01 AG068398
Pays : United States
Informations de copyright
© 2023 the author(s), published by De Gruyter, Berlin/Boston.
Références
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
J Neurol. 2019 Aug;266(8):2075-2086
pubmed: 31119452
Curr Genet Med Rep. 2019 Mar;7(1):41-52
pubmed: 31687268
Neurobiol Aging. 2014 Nov;35(11):2658.e1-2658.e5
pubmed: 25085782
Neurology. 2011 Feb 1;76(5):467-74
pubmed: 21178100
Curr Opin Neurobiol. 2022 Feb;72:131-139
pubmed: 34826653
J Alzheimers Dis. 2015;50(2):539-46
pubmed: 26682689
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Dement Geriatr Cogn Dis Extra. 2016 Jul 22;6(2):330-340
pubmed: 27703466
Nat Commun. 2016 Jun 30;7:11992
pubmed: 27356620
Neurology. 2014 May 27;82(21):1871-8
pubmed: 24771538
Neurobiol Aging. 2020 Jul;91:167.e1-167.e9
pubmed: 32171590
Nature. 2006 Aug 24;442(7105):916-9
pubmed: 16862116
Neurology. 2018 Jan 16;90(3):118-125
pubmed: 29263224
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Front Neurol. 2015 Aug 19;6:179
pubmed: 26347708
Mol Neurodegener. 2014 Sep 20;9:38
pubmed: 25239657
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Expert Opin Ther Targets. 2018 Jul;22(7):579-585
pubmed: 29889573
J Mol Med (Berl). 2003 Oct;81(10):600-12
pubmed: 12928786
eNeuro. 2017 Aug 18;4(4):
pubmed: 28828399
Brain. 2009 Mar;132(Pt 3):583-91
pubmed: 19158106
Lancet Neurol. 2008 Oct;7(10):965-74
pubmed: 18771956
Neurobiol Aging. 2022 Feb;110:113-121
pubmed: 34620513
Neurobiol Aging. 2019 Jun;78:98-110
pubmed: 30925302
Neurodegener Dis. 2012;9(3):121-7
pubmed: 22123177
Trends Pharmacol Sci. 2022 Aug;43(8):641-652
pubmed: 35039149
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
J Biol Chem. 2012 Sep 21;287(39):32298-306
pubmed: 22859297
Mol Neurodegener. 2019 Jan 16;14(1):4
pubmed: 30651094
J Neurol Neurosurg Psychiatry. 2020 Sep;91(9):960-967
pubmed: 32611664
Oncotarget. 2015 May 10;6(13):10825-39
pubmed: 25839164
J Neurochem. 2016 Aug;138 Suppl 1:54-70
pubmed: 27306735
Acta Neuropathol. 2018 Jul;136(1):1-17
pubmed: 29744576